TPCK

TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is an effective serine protease inhibitor and also a blocker of the PDK1/Akt pathway. TPCK can modify the E7 protein in actively keratinocyte cells. TPCK can induce cellular apoptosis, suppress tumor growth, reduce hypoxic-ischemic brain injury in rat pups, and affect vascular permeability in inflamed rats[1][2][3][4][5].

Product Specifications

CAS Number

[402-71-1]

Product Name Alternative

L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK

UNSPSC

12352005

Hazard Statement

H315, H318, H335

Target

Apoptosis; HPV; PDK-1; Ser/Thr Protease

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tpck.html

Purity

99.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=CC=C(C=C1)S(N[C@@H](CC2=CC=CC=C2)C(CCl)=O)(=O)=O

Molecular Formula

C17H18ClNO3S

Molecular Weight

351.85

Precautions

H315, H318, H335

References & Citations

[1]H Stöppler, et al. The serine protease inhibitors TLCK and TPCK react with the RB-binding core of HPV-18 E7 protein and abolish its RB-binding capability. Virology. 1996 Mar 15;217 (2) :542-53.|[2]Patrícia de A Machado, et al. Effects of a Serine Protease Inhibitor N- p-Tosyl-L-phenylalanine Chloromethyl Ketone (TPCK) on Leishmania amazonensis and Leishmania infantum. Pharmaceutics.2022 Jun 29;14 (7) :1373.|[3]H Stöppler, et al. The serine protease inhibitors TLCK and TPCK react with the RB-binding core of HPV-18 E7 protein and abolish its RB-binding capability. Virology. 1996 Mar 15;217 (2) :542-53.|[4]M H LeBlanc, et al. N-tosyl-L-phenylalanyl-chloromethylketone reduces hypoxic-ischemic brain injury in rat pups. Eur J Pharmacol. 2000 Mar 3;390 (3) :249-56|[5]K Watanabe, et al. Vascular permeability changes by proteinase inhibitors in carrageenin-induced inflammation in rats. Agents Actions. 1986 Mar;17 (5-6) :472-7.